HMGB1, high mobility group box 1, 3146

N. diseases: 724; N. variants: 10
Disease: Multiple Sclerosis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 Biomarker disease BEFREE Here, we studied the contribution of circulating high mobility group box protein 1 (HMGB1) and mitochondrial DNA (mtDNA) to neuroinflammation in progressive MS. We measured plasmatic mtDNA, HMGB1 and pro-inflammatory cytokines in 38 secondary progressive (SP) patients, 35 primary progressive (PP) patients and 42 controls.Free mtDNA was higher in SP than PP. 31726376 2020
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 Biomarker disease BEFREE Our results suggest chronic low-grade inflammation in MS patients that correlates with clinical conditions of MS patients, and for HMGB1 as a possible target molecule in future therapy. 31728855 2020
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 Biomarker disease BEFREE Herein, we attempt to shed more light on the molecular crosstalk of HMGB1 protein in the pathogenesis of MS/EAE suggesting that HMGB1 blockade could impede the pro-inflammatory loop that drives MS autoimmunity. 31606383 2019
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 AlteredExpression disease BEFREE The results of this study showed that HMGB1 protein levels of PBMC and CSF in patients with MS were significantly higher than those of controls (SMD = 4.36, 95% CI = 3.69-5.02, and SMD = 0.85, 95% CI = 0.42-1.28, respectively), but we found no significant difference in HMGB1 mRNA level of PBMC and serum HMGB1 protein level between MS patients and controls. 30953953 2019
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 Biomarker disease BEFREE In conclusion, rTM down-regulated inflammatory mediators in the peripheral circulation and prevented HMGB1 release from nuclei in the central nervous system, suppressing EAE-related inflammation. rTM could have a novel therapeutic potential for patients with MS. 29509323 2018
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 AlteredExpression disease BEFREE Taken together, the results indicate that GL has a strong neuroprotective effect on EAE mice by reducing HMGB1 expression and release and thus can be used to treat central nervous system inflammatory diseases, such as MS. 30013568 2018
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 Biomarker disease BEFREE These results point to a role of HMGB1 mRNA and protein levels as disease activity biomarkers to discriminate the more inflammatory relapse-onset MS forms, particularly RRMS, from the less inflammatory PPMS form of the disease. 25879961 2015
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 AlteredExpression disease BEFREE Serum HMGB1 levels in MS patients were significantly higher than those in ONNDs patients (p=0.002). 23255728 2013
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 AlteredExpression disease BEFREE Significant expression of HMGB1 and its receptors on accumulating activated macrophages and resident microglia may thus provide a positive feedback loop that amplifies the inflammatory response during MS and EAE pathogenesis. 18644848 2008
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.090 AlteredExpression disease LHGDN Significant expression of HMGB1 and its receptors on accumulating activated macrophages and resident microglia may thus provide a positive feedback loop that amplifies the inflammatory response during MS and EAE pathogenesis. 18644848 2008